

Novartis BAF312 reduced the risk of disability progression in pivotal phase III study in secondary progressive MS patients

Sep 17, 2016

Source URL: <https://qa1.novartis.us/us-en/news/media-releases/novartis-baf312-reduced-risk-disability-progression-pivotal-phase-iii-study-secondary-progressive-ms-patients-0>

List of links present in page

1. <https://qa1.novartis.us/us-en/us-en/news/media-releases/novartis-baf312-reduced-risk-disability-progression-pivotal-phase-iii-study-secondary-progressive-ms-patients-0>